Diversify Wealth Management LLC Has $194,000 Holdings in Grifols, S.A. $GRFS

Diversify Wealth Management LLC cut its stake in Grifols, S.A. (NASDAQ:GRFS) by 77.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,509 shares of the biotechnology company’s stock after selling 85,636 shares during the period. Diversify Wealth Management LLC’s holdings in Grifols were worth $194,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Sequoia Financial Advisors LLC increased its holdings in shares of Grifols by 26.5% in the first quarter. Sequoia Financial Advisors LLC now owns 39,742 shares of the biotechnology company’s stock valued at $319,000 after purchasing an additional 8,323 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Grifols by 31.3% during the 1st quarter. QRG Capital Management Inc. now owns 43,614 shares of the biotechnology company’s stock worth $350,000 after buying an additional 10,403 shares in the last quarter. OLD National Bancorp IN acquired a new position in Grifols during the 1st quarter worth $104,000. BI Asset Management Fondsmaeglerselskab A S boosted its position in Grifols by 466.3% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 316,111 shares of the biotechnology company’s stock valued at $2,535,000 after buying an additional 260,295 shares during the last quarter. Finally, Corient Private Wealth LLC increased its stake in shares of Grifols by 30.9% in the 4th quarter. Corient Private Wealth LLC now owns 63,885 shares of the biotechnology company’s stock valued at $597,000 after buying an additional 15,086 shares during the period.

Analyst Ratings Changes

Several brokerages have recently issued reports on GRFS. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings lowered shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $10.00.

Grifols Trading Up 4.7%

NASDAQ GRFS opened at $7.61 on Tuesday. Grifols, S.A. has a 12 month low of $6.96 and a 12 month high of $11.14. The stock has a 50-day simple moving average of $7.51 and a 200 day simple moving average of $8.26. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16. The company has a market capitalization of $5.18 billion, a PE ratio of 40.05, a P/E/G ratio of 0.28 and a beta of 0.67.

Grifols Announces Dividend

The business also recently declared a special dividend, which was paid on Thursday, July 9th. Stockholders of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s dividend payout ratio is 121.05%.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.